Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Differences in overall survival and cancer-specific survival in high-risk prosta...
Journal Information
Vol. 43. Issue 2.
Pages 91-98 (March 2019)
Download PDF
More article options
Vol. 43. Issue 2.
Pages 91-98 (March 2019)
Original article
Differences in overall survival and cancer-specific survival in high-risk prostate cancer patients according to the primary treatment
Diferencias en la supervivencia global y supervivencia cáncer específica en pacientes con cáncer de próstata de alto riesgo según el tratamiento primario aplicado
J. Caño-Velasco
Corresponding author

Corresponding author.
, F. Herranz-Amo, G. Barbas-Bernardos, L. Polanco-Pujol, J. Hernández-Cavieres, E. Lledó-García, C. Hernández-Fernández
Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Article information
Full Text
Download PDF
Tables (6)
Table 1. Comparison of clinical variables according to the primary treatment.
Table 2. Pathologic variables of patients treated with prostatectomy.
Table 3. Salvage therapies, patients’ condition at the end of the study and death causes.
Table 4. Estimation of crude OS and CSS of the series at 5, 10 and 15 years according to the primary treatment (a). Crude overall survival according to primary treatment (b). Crude cancer-specific survival according to primary treatment (c).
Table 5. Uni and multivariate analysis of the variables that can influence on OS.
Table 6. Uni and multivariate analysis of the variables that can influence on CSS.
Show moreShow less
Figures (2)
Introduction and objectives

There is no high-level evidence as to which primary treatment provides an overall survival (OS) or cancer-specific survival (CSS) advantage in high-risk localised prostate cancer (HRLPC).

Our aim was to analyse the differences in survival and predictive factors in this group of patients, according to their primary treatment (radical prostatectomy (RP) or radiotherapy and androgen blockade (RT+HT)).

Material and methods

A retrospective study of 286 HRLPC patients diagnosed between 1996 and 2008, treated by RP (n=145) or RT+HT (n=141).

Survival was assessed using the Kaplan–Meier method. Significant differences between the different variables were analysed using the log-rank test. A uni and multivariate Cox regression analysis was performed to identify risk factors.


The median follow-up was 117.5 (IQR 87–158) months. The OS was longer (p=0.04) in the RP patients, while there were no differences (p=0.44) in CSS between either group.

The type of primary treatment was not related to OS or CSS. Age (p=0.002), the onset during follow-up of a 2nd tumour (p=0.0001), and stage cT3a (p=0.009) behaved as independent predictive variables of OS. None of the variables behaved as an independent predictive variable of CSS, although biochemical recurrence after rescue treatment (p=0.058), and the onset of a 2nd tumour during follow-up showed a significant trend to statistical significance, the latter reducing specific cancer mortality (HR .16, 95%CI 0.02–1.18, p=0.07).


Primary treatment did not relate to OS or CSS in patients with HRPC.

Prostate cancer
External radiotherapy
Introducción y objetivos

No existe evidencia de alto nivel sobre qué tratamiento primario proporciona una ventaja de supervivencia global (SG) y supervivencia cáncer específica (SCE) en cáncer de próstata localizado de alto riesgo (CPAR).

Nuestro objetivo es analizar las diferencias en supervivencia, así como sus factores predictores, en este grupo de pacientes según su tratamiento primario (prostatectomía radical [PR] o radioterapia y bloqueo androgénico [RT+HT]).

Material y métodos

Estudio retrospectivo de 286 pacientes con CPAR diagnosticados entre 1996-2008, tratados mediante PR (n=145) o RT+HT (n=141).

La supervivencia se evaluó con el método de Kaplan-Meier. La existencia de diferencias significativas entre las distintas variables se analizó mediante el test de log-rank. Para la identificación de factores de riesgo se utilizó un análisis uni y multivariante mediante regresión de Cox.


La mediana de seguimiento fue de 117,5 (IQR 87-158) meses. La SG fue mayor (p=0,04) en los pacientes con PR, mientras que no existieron diferencias (p=0,44) en la SCE entre ambos grupos.

El tipo de tratamiento primario no se relacionó con la SG ni SCE. La edad (p=0,002), la aparición durante el seguimiento de un segundo tumor (p=0,0001) y el estadio cT3a (p=0,009) se comportaron como variables predictoras independientes de SG. Ninguna de las variables se comportó como variable predictora independiente de SCE, aunque la recidiva bioquímica tras tratamiento de rescate (p=0,058) y la aparición de un segundo tumor durante el seguimiento presentaron una tendencia importante a la significación estadística, reduciendo este último la mortalidad cáncer específica (hazard ratio 0,16, intervalo de confianza del 95% 0,02-1,18, p=0,07).


El tratamiento primario no se relacionó con la SG ni SCE en pacientes con CPAR.

Palabras clave:
Cáncer de próstata
Radioterapia externa


These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos